# A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

> **NCT05669625** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **China National Biotec Group Company Limited** · enrollment: 12440 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** Investigational live attenuated varicella vaccine
- **BIOLOGICAL:** Placebo of live attenuated varicella vaccine

## Key facts

- **NCT ID:** NCT05669625
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-26
- **Primary completion:** 2024-04-14
- **Final completion:** 2026-09-14
- **Target enrollment:** 12440 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669625, "A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05669625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*